Research in childhood cancer treatments has not advanced very much in the past years.
Innovative protocols in Switzerland need to be funded. It is essential to increase the cure rate of children with cancer, so that they can all be cured one day.
Every week in Switzerland, one child dies of cancer. 80% of children with cancer can be cured, but, half of them have long term side effects as a result of their treatment or cancer.
Some cancers have a very poor prognosis from the moment they are diagnosed. Despite successful treatment, relapses are common. Zoé4life is involved with the Swiss Paediatric Oncology Group to advance research specifically for these types of cancer.
New research projects are rapidly being put in place for children in Switzerland thanks to our financial support. They are set up in Swiss hospitals so that children currently undergoing treatment and those of tomorrow can benefit from them.
The results of these treatments are evaluated at the international level to determine the best course of action to improve the cure rate for all children.
A child’s immune system has the potential to cure his cancer. In collaboration with the CHUV in Lausanne and the Seattle Children’s Hospital in the United States, Zoé4life has established a partnership to introduce a new type of cancer immunotherapy in Switzerland.
Immunotherapy is an innovative field in the treatment of cancer. Through cellular engineering, this treatment allows the body’s immune system to cure itself without the difficult and often permanent side effects of chemotherapy and radiotherapy.
Most patients experience an improvement in their disease within a few weeks.
Not only do most immunotherapy patients see their cancer go into remission quickly, but the side effects of treatment are less harmful than aggressive chemotherapy or radiation.
Finally, more effective and gentler cancer treatment is within our reach. And we are already seeing results: a recent Seattle clinical trial of pediatric leukemia resulted in a 93% complete remission rate in children with relapsing leukemia.